Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136244 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marta Garcia de Herreros und 23 weiteren Autor:innen. Beteiligte Einrichtung: Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques Augu…. Hauptthemen laut MEDLINE: PTEN Phosphohydrolase, Transcriptome, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ''Ayudas SEOM de Intensificación para Investigadores Jóvenes'', European Union, Janssen-Pharmaceuticals.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Alterations in the PTEN tumor suppressor gene are common in prostate cancer. They have been associated with a more aggressive disease and poor outcomes and potential benefit of targeted therapies. The purpose of this work is to study the clinical and transcriptional landscapes associated to low PTEN mRNA expression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. A multicenter biomarker ambispective study was performed in mHSPC patients. PTEN mRNA expression was assessed by nCounter in formalin-fixed paraffin-embedded tumor samples. PTENlow status was defined by a previously validated cut-off and was correlated with castration-resistant prostate cancer (CRPC)-free survival (CRPC-FS) (primary endpoint) and overall survival (OS). RNA-Seq was performed to molecularly characterize PTENlow vs. PTENwt tumors. A total of 380 patients were included, 350 eligible. PTENlow was observed in 28.2% of patients and was independently associated with shorter CRPC-FS (HR 1.6, 95% CI 1.2–2.1, p = 0.002) and OS (HR 1.5, 95% CI 1.1–2, p = 0.014). PTENlow tumors showed overexpression of neuroendocrine, cell cycle, and DNA repair gene signatures, reduced expression of the androgen receptor pathway, and a distinct immune microenvironment. Using microarray data from the CHAARTED trial, we developed a PTEN-low related signature, independently associated with CRPC-FS (HR 1.5, 95% CI 1–2.3, p = 0.036) and OS (HR 1.9, C1 1.2–2.9, p = 0.005), and identified targets for potential therapies in PTEN-altered tumors. We conclude that PTENlow correlates with an aggressive clinical outcome in mHSPC patients and is associated with a unique transcriptional profile. These findings further support the investigation of novel therapeutic strategies for patients with PTEN alterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.
- Medical Oncology Department, Hospital Clínic, 08036 Barcelona, Spain.
- Uro-Oncology Unit, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.
- Department of Medicine, University of Barcelona, 08036 Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Department of Pathology, Hospital Clínic, 08036 Barcelona, Spain.
ORCID-Profile: Natalia Jiménez, Joan Padrosa, Laura Ferrer-Mileo, Samuel García-Esteve, Isabel Trias, Laia Fernández-Mañas, Isabel Chirivella, Mariona Figols, Vicenç Ruiz de Porras, Aleix Prat, Begoña Mellado
Förderung
- ''Ayudas SEOM de Intensificación para Investigadores Jóvenes''
- European Union
- Janssen-Pharmaceuticals
- NCI NIH HHS
- CERCA Programme/Generalitat de Catalunya
- Instituto de Salud Carlos III
- Contracte Clínic Recerca "Emili Letang i Josep Font" 2023
- Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación
Zitieren
APA
Garcia de Herreros, M., Jiménez, N., Padrosa, J., Aversa, C., Ferrer-Mileo, L., García-Esteve, S., Rodríguez-Carunchio, L., Trias, I., Fernández-Mañas, L., Marín-Aguilera, M., Altamirano, M., Mazariegos, M., Font, A., Rodriguez-Vida, A., Climent, M. Á., Cros, S., Chirivella, I., Figols, M., Sala-González, N., …, & Mellado, B. (2025). Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136244
Vancouver
Garcia de Herreros M, Jiménez N, Padrosa J, Aversa C, Ferrer-Mileo L, García-Esteve S, et al. Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136244
BibTeX
@article{GarciadeHerreros2025,
author = {Garcia de Herreros, Marta and Jiménez, Natalia and Padrosa, Joan and Aversa, Caterina and Ferrer-Mileo, Laura and García-Esteve, Samuel and Rodríguez-Carunchio, Leonardo and Trias, Isabel and Fernández-Mañas, Laia and Marín-Aguilera, Mercedes and Altamirano, Mariana and Mazariegos, Manuel and Font, Albert and Rodriguez-Vida, Alejo and Climent, Miguel Ángel and Cros, Sara and Chirivella, Isabel and Figols, Mariona and Sala-González, Núria and Ruiz de Porras, Vicenç and Pardo, Juan Carlos and Prat, Aleix and Reig, Òscar and Mellado, Begoña},
title = {Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136244}
}
EUVIMED